Jaguar Gene Therapy

Jaguar Gene Therapy, LLC is a gene therapy company based in Lake Forest, Illinois, founded by former executives of AveXis (developer of the spinal muscular atrophy therapy Zolgensma, acquired by Novartis in 2018). The company states its mission as accelerating breakthroughs in gene therapy for patients with severe genetic diseases, and it emphasizes core values of integrity, agility and collaboration.

The company's initial pipeline uses adeno-associated virus serotype 9 (AAV9) vectors to deliver functional gene copies intended to provide long-lasting benefit from a single administration. Three disclosed programs are in preclinical development: JAG201, targeting severe neurodevelopmental disorders driven by SHANK3 mutation or deletion (including autism spectrum disorder and Phelan-McDermid syndrome), exclusively licensed from the Broad Institute of MIT and Harvard; JAG101, a GALT gene replacement approach for Type 1 galactosemia, supported by research agreements with Emory University and the University of Utah; and JAG301, which uses the PAX4 gene to transdifferentiate pancreatic alpha cells into insulin-producing beta cells for Type 1 diabetes, exclusively licensed from Tulane University. Axovia Therapeutics, a majority-owned subsidiary launched alongside Jaguar, is developing AXV101 for BBS1, a subset of Bardet-Biedl syndrome, building on the work of Philip Beales at University College London.

Jaguar states it invests early in scalable, commercially viable manufacturing and next-generation purification processes to limit product- and process-related impurities, and says it can manufacture at multiple scales. It also says it continuously evaluates next-generation delivery technologies, including novel capsids. The company has announced plans for a commercial manufacturing facility in North Carolina.

Founding story

Jaguar was formed by former AveXis leadership, including Sean P. Nolan, a former AveXis CEO who serves as Jaguar's executive chairman, and Joe Nolan (unrelated), a former AveXis general manager who serves as chief executive officer. Four other former AveXis executives rounded out the initial leadership team, including Suku Nagendran as head of research and development. The company built out its research pipeline and team quietly for more than a year before launching publicly on February 25, 2021, backed by just over $40 million from Deerfield Management, an early AveXis investor. Sean Nolan framed the company's aim as pursuing larger patient populations and diseases where gene therapy had not previously been applied.

Business model

Jaguar is a privately held, venture-backed therapeutics developer with no approved products. It in-licenses or partners on academic gene therapy programs (Broad Institute, Tulane University, Emory University, University of Utah) and advances them through preclinical and clinical development, funding operations through equity financing. It also holds a majority stake in the subsidiary Axovia Therapeutics, which can draw on Jaguar's manufacturing, clinical and regulatory capabilities.

Traction

All disclosed Jaguar programs remain preclinical. Encouraging preclinical proof-of-concept animal data has been produced at the partner institutions for JAG201 (Broad Institute), JAG101 (Emory University and University of Utah) and JAG301 (Tulane University). The company raised just over $40 million prior to public launch and closed a $139 million Series B in April 2021. It has announced a planned commercial gene therapy manufacturing facility in North Carolina. The company's careers page listed no open roles at the time of capture.

Latest developments

Leadership and team pages on the company website were published in February 2025, listing Joe Nolan as CEO plus functional leads across strategy and operations, clinical development and medical affairs, quality and regulatory affairs, analytical development, manufacturing partnerships and other areas. The pipeline page describes JAG201, JAG101 and JAG301 as in preclinical development.